Critical Survey: Eliem Therapeutics (NASDAQ:ELYM) and Palatin Technologies (OTCMKTS:PTNT)

Valuation and Earnings

This table compares Eliem Therapeutics and Palatin Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12 million	($0.53)	-15.19
Palatin Technologies	$4.49 million	49.41	-$29.74 million	($1.55)	-5.50

Palatin Technologies has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Palatin Technologies, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Palatin Technologies shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 7.1% of Palatin Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Eliem Therapeutics and Palatin Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Palatin Technologies	N/A	N/A	-365.57%

Volatility and Risk

Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Summary

Palatin Technologies beats Eliem Therapeutics on 6 of the 9 factors compared between the two stocks.

About Eliem Therapeutics

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.